We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

altona Diagnostics GmbH

altona Diagnostics GmbH develops and commercializes real-time PCR based assays and molecular diagnostic test solution... read more Featured Products: More products

Download Mobile App





Altona Diagnostics Receives Emergency Use Authorization from US FDA for RealStar SARS-CoV-2 RT-PCR Kit US

By LabMedica International staff writers
Posted on 01 May 2020
Altona Diagnostics GmbH (Hamburg, Germany) has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its RealStar SARS-CoV-2 RT-PCR Kit US. More...


The real-time Reverse Transcription/Polymerase Chain Reaction (RT-PCR) based molecular diagnostic test can be used under the EUA by authorized US laboratories for the in vitro qualitative detection of SARS-CoV-2 RNA in upper respiratory samples from individuals, who are suspected of COVID-19

The RealStar SARS-CoV-2 RT-PCR Kit US is authorized to be used within a workflow consisting of nucleic acid extraction using the AltoStar Automation System AM16 in combination with the AltoStar Purification Kit 1.5 and the AltoStar Internal Control 1.5 from altona,s followed by amplification and detection of SARS-CoV-2 specific RNA with the CFX96 real-time PCR instruments from Bio-Rad.


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.